These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 11858482

  • 1. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D.
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [Abstract] [Full Text] [Related]

  • 2. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C, Mouret P.
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [Abstract] [Full Text] [Related]

  • 3. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
    Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D, Melagatran for Thrombin inhibition in Orthopaedic surgery.
    Lancet; 2002 Nov 09; 360(9344):1441-7. PubMed ID: 12433510
    [Abstract] [Full Text] [Related]

  • 4. [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement].
    Mouret P.
    Hamostaseologie; 2002 Aug 09; 22(3):21-4. PubMed ID: 12215757
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug 09; 14(78):127-32. PubMed ID: 16106594
    [Abstract] [Full Text] [Related]

  • 7. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC, Perry CM, Faulds D.
    Drugs; 2004 Aug 09; 64(6):649-78. PubMed ID: 15018597
    [Abstract] [Full Text] [Related]

  • 8. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW, EXULT A Study Group.
    N Engl J Med; 2003 Oct 30; 349(18):1703-12. PubMed ID: 14585938
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
    Eriksson UG, Mandema JW, Karlsson MO, Frison L, Gisleskog PO, Wählby U, Hamrén B, Gustafsson D, Eriksson BI.
    Clin Pharmacokinet; 2003 Oct 30; 42(7):687-701. PubMed ID: 12844328
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
    Eriksson BI.
    Thromb Res; 2003 Jul 15; 109 Suppl 1():S23-9. PubMed ID: 12818631
    [Abstract] [Full Text] [Related]

  • 11. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M, Freij A, EXPRESS Study Group.
    J Thromb Haemost; 2003 Dec 15; 1(12):2490-6. PubMed ID: 14675083
    [Abstract] [Full Text] [Related]

  • 12. Ximelagatran in orthopaedic surgery.
    Eriksson B.
    Pathophysiol Haemost Thromb; 2005 Dec 15; 34 Suppl 1():10-7. PubMed ID: 15812199
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
    Wåhlander K, Larson G, Lindahl TL, Andersson C, Frison L, Gustafsson D, Bylock A, Eriksson BI.
    Thromb Haemost; 2002 Apr 15; 87(4):580-5. PubMed ID: 12008938
    [Abstract] [Full Text] [Related]

  • 15. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N.
    Anaesthesia; 2004 Aug 15; 59(8):803-10. PubMed ID: 15270973
    [Abstract] [Full Text] [Related]

  • 16. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1713-21. PubMed ID: 14585939
    [Abstract] [Full Text] [Related]

  • 17. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
    Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, Samuelsson O.
    Clin Pharmacokinet; 2003 Oct 30; 42(8):743-53. PubMed ID: 12846595
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
    Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G, AstraZeneca Arthroplasty Study Group.
    Arch Intern Med; 2001 Oct 08; 161(18):2215-21. PubMed ID: 11575978
    [Abstract] [Full Text] [Related]

  • 19. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
    Teng R, Sarich TC, Eriksson UG, Hamer JE, Gillette S, Schützer KM, Carlson GF, Kowey PR.
    J Clin Pharmacol; 2004 Sep 08; 44(9):1063-71. PubMed ID: 15317834
    [Abstract] [Full Text] [Related]

  • 20. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B.
    Drugs; 2004 Sep 08; 64 Suppl 1():27-35. PubMed ID: 15586625
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.